TW201509441A - Emulsification composition - Google Patents
Emulsification composition Download PDFInfo
- Publication number
- TW201509441A TW201509441A TW103114227A TW103114227A TW201509441A TW 201509441 A TW201509441 A TW 201509441A TW 103114227 A TW103114227 A TW 103114227A TW 103114227 A TW103114227 A TW 103114227A TW 201509441 A TW201509441 A TW 201509441A
- Authority
- TW
- Taiwan
- Prior art keywords
- emulsified composition
- mass
- present
- ceresin
- emulsified
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 238000004945 emulsification Methods 0.000 title 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 36
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- 235000011187 glycerol Nutrition 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 235000019271 petrolatum Nutrition 0.000 claims abstract description 16
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 claims abstract description 15
- 239000003871 white petrolatum Substances 0.000 claims abstract description 12
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940032094 squalane Drugs 0.000 claims abstract description 11
- 239000012188 paraffin wax Substances 0.000 claims description 19
- 229920000223 polyglycerol Polymers 0.000 claims description 13
- 238000000926 separation method Methods 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000002537 cosmetic Substances 0.000 abstract description 5
- 238000009472 formulation Methods 0.000 abstract description 3
- 229940057995 liquid paraffin Drugs 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 18
- 239000012071 phase Substances 0.000 description 11
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 10
- 239000001993 wax Substances 0.000 description 9
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 229940105990 diglycerin Drugs 0.000 description 5
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 5
- 229940075507 glyceryl monostearate Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- -1 fatty acid ester Chemical class 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- FJXSLZRUXGTLPF-HKIWRJGFSA-N (z)-octadec-9-enoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O FJXSLZRUXGTLPF-HKIWRJGFSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- AFQMWBUNDONXED-UHFFFAOYSA-N 2-phenylmethoxyethanamine;hydrochloride Chemical compound Cl.NCCOCC1=CC=CC=C1 AFQMWBUNDONXED-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 101100476202 Caenorhabditis elegans mog-2 gene Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- WVRJNKBXUMGBGG-UHFFFAOYSA-N [3-(2,3-dihydroxypropoxy)-2-hydroxypropyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)COCC(O)CO WVRJNKBXUMGBGG-UHFFFAOYSA-N 0.000 description 1
- 229940022682 acetone Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229950000250 dexamethasone dipropionate Drugs 0.000 description 1
- CIWBQSYVNNPZIQ-PKWREOPISA-N dexamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-PKWREOPISA-N 0.000 description 1
- 229950006825 dexamethasone valerate Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000004495 emulsifiable concentrate Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- SRAXAXHQMCQHSH-UHFFFAOYSA-N n-benzyl-2-chloroacetamide Chemical compound ClCC(=O)NCC1=CC=CC=C1 SRAXAXHQMCQHSH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012186 ozocerite Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- TXGSOSAONMOPDL-UHFFFAOYSA-N propan-2-yl 3,4,5-trihydroxybenzoate Chemical compound CC(C)OC(=O)C1=CC(O)=C(O)C(O)=C1 TXGSOSAONMOPDL-UHFFFAOYSA-N 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 235000002316 solid fats Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
Description
本發明係有關可抑制經時性分離,可提升性質穩定性之乳化組成物。 The present invention relates to an emulsified composition which can suppress the separation over time and can improve the stability of properties.
乳化組成物可大致區分為O/W型與W/O型。W/O型乳化組成物由於外相係以油、內相係以水所構成,易於斥水,雖有保護患部之作用,屬如軟膏劑般無黏膩感之製劑。如此,由於W/O型乳化組成物其使用感良好,可望於醫藥品或化妝品領域廣泛加以活用。另一方面,就W/O型乳化組成物之穩定性而言,則有容易自內水相經時性地發生水分離(水自製劑中滲出)之課題。特別是,為了賦予清爽的使用感,而增加內水相之水的含量時,則容易進一步發生分離。 The emulsified composition can be roughly classified into an O/W type and a W/O type. The W/O type emulsified composition is composed of oil and internal phase water, and is easy to be water-repellent. Although it has the function of protecting the affected part, it is a preparation which is not sticky like an ointment. As described above, the W/O type emulsified composition has a good feeling of use and is expected to be widely used in the field of pharmaceuticals or cosmetics. On the other hand, in terms of the stability of the W/O type emulsified composition, there is a problem that water separation (water oozing out from the preparation) is likely to occur from the internal water phase over time. In particular, in order to impart a refreshing feeling of use and increase the content of water in the internal water phase, separation is more likely to occur.
向來,作為提升W/O型乳化組成物之穩定性的方法,已知有一種對液狀油性基劑添加液狀油性成分之膠化劑使其膠化,再與使用特定之油中水型界面活性劑經膠化的水混合而予以乳化的方法(專利文獻1)。然,上述W/O 型乳化組成物由於使用糊精脂肪酸酯之類的油性膠化劑作為膠化劑,會產生黏膩感,而有使用感方面之課題。 Conventionally, as a method for improving the stability of a W/O type emulsified composition, a gelling agent for adding a liquid oily component to a liquid oily base is known to be gelled, and a specific type of oil is used. A method in which a surfactant is emulsified by mixing gelatinized water (Patent Document 1). However, the above W/O Since the emulsified composition uses an oil gelling agent such as a dextrin fatty acid ester as a gelling agent, it has a sticky feeling and has a problem in use.
迄今,已有一種透過使用甘油單油酸酯及烷基上具有分支鏈之界面活性劑而得之高含水量W/O型乳化組成物之報導(專利文獻2),惟對於摻混甘油且任意選擇性地摻混流動石蠟、鯊烷、白凡士林,並以聚甘油單油酸酯為乳化劑的W/O型乳化組成物,摻混地蠟以抑制經時性分離之實例仍未有其報導。 Heretofore, there has been reported a high water content W/O type emulsified composition obtained by using a glycerol monooleate and a surfactant having a branched chain on an alkyl group (Patent Document 2), but for blending glycerin and An example of a W/O type emulsified composition in which a paraffin wax, a squalane, a white petrolatum, and a polyglycerol monooleate are used as an emulsifier, and an example in which a ground wax is blended to suppress the separation over time is not present. Its report.
[先前技術文獻] [Previous Technical Literature]
[專利文獻] [Patent Literature]
[專利文獻1]日本專利3509108號 [Patent Document 1] Japanese Patent No. 3509108
[專利文獻2]日本特開2007-153824號公報 [Patent Document 2] Japanese Patent Laid-Open Publication No. 2007-153824
本發明係以提供一種在包含聚甘油單油酸酯與甘油的乳化組成物中,可抑制經時性分離,性質穩定性優良的乳化組成物。 The present invention provides an emulsified composition which is excellent in property stability in suppressing chronological separation in an emulsified composition containing polyglycerol monooleate and glycerin.
本發明者為解決上述課題而致力進行研究的結果發現,藉由對含有聚甘油單油酸酯與甘油的乳化組成 物摻混地蠟,可製成不會發生分離,縱使經長期保存其性質仍穩定的乳化組成物,而完成本發明。 As a result of intensive studies to solve the above problems, the present inventors have found that an emulsified composition containing polyglycerol monooleate and glycerin is obtained. The present invention can be prepared by blending a ground wax with an emulsified composition which does not undergo separation and which is stable even after long-term storage.
即,本發明係:(1)一種乳化組成物,其特徵為含有(a)聚甘油單油酸酯、(b)甘油、(c)地蠟、及(d)水;(2)如(1)之乳化組成物,其係W/O型;(3)如(1)或(2)之乳化組成物,其中,進一步包含選自流動石蠟、鯊烷及白凡士林所成之群中至少1種油性成分;(4)如(1)之乳化組成物,其中相對於乳化組成物總質量,地蠟之含量為0.1~20質量%;(5)如(1)之乳化組成物,其中相對於乳化組成物總質量,聚甘油單油酸酯之含量為0.5~40質量%;(6)如(1)之乳化組成物,其中相對於1質量份之聚甘油單油酸酯,地蠟之含量為0.1~5質量份。 That is, the present invention is: (1) an emulsified composition characterized by containing (a) polyglycerol monooleate, (b) glycerin, (c) ceresin, and (d) water; (2) as ( 1) an emulsified composition, which is a W/O type; (3) an emulsified composition according to (1) or (2), further comprising at least one selected from the group consisting of mobile paraffin, squalane and white petrolatum. (1) The emulsified composition of (1), wherein the content of the ground wax is 0.1 to 20% by mass based on the total mass of the emulsified composition; (5) the emulsified composition of (1), wherein The content of the polyglycerol monooleate is from 0.5 to 40% by mass based on the total mass of the emulsified composition; (6) The emulsified composition of (1), wherein, relative to 1 part by mass of the polyglycerol monooleate, The wax content is 0.1 to 5 parts by mass.
根據本發明,可提供一種可抑制分離、性質穩定性優良,甚而使用感亦良好的乳化組成物。 According to the present invention, it is possible to provide an emulsified composition which can suppress separation, has excellent property stability, and is excellent in handling feeling.
作為本發明之聚甘油單油酸酯,可列舉二甘油單油酸酯、四甘油單油酸酯等,此等當中較佳為二甘油單油酸酯。作為聚甘油單油酸酯,亦可利用例如NIKKOL DGMO-CV(商品名:Nikko Chemicals股份有限公司製)、EMALEX MOG-2(商品名:NIHON EMULSION股份有限公司製)等市售品。相對於本發明乳化組成物全體,聚甘油單油酸酯之含量較佳為0.5~40質量%,更佳為1~20質量%,最佳為1.5~10質量%。 Examples of the polyglycerol monooleate of the present invention include diglycerin monooleate and tetraglycerol monooleate, and among these, diglycerin monooleate is preferred. As a polyglycerol monooleate, for example, NIKKOL can also be utilized. Commercial products such as DGMO-CV (trade name: manufactured by Nikko Chemicals Co., Ltd.) and EMALEX MOG-2 (trade name: manufactured by NIHON EMULSION Co., Ltd.). The content of the polyglycerol monooleate is preferably from 0.5 to 40% by mass, more preferably from 1 to 20% by mass, most preferably from 1.5 to 10% by mass, based on the entire emulsified composition of the present invention.
作為本發明之甘油,可使用甘油及/或濃甘油,無特殊限制,惟更佳為濃甘油。作為該甘油亦可利用甘油(商品名:阪本藥品工業製)、日本藥典所載濃甘油(商品名:花王股份有限公司製)等市售品。相對於本發明乳化組成物全體,甘油之含量較佳為5~25質量%。 As the glycerin of the present invention, glycerin and/or concentrated glycerin can be used without particular limitation, and more preferably concentrated glycerin. Commercially available products such as glycerin (trade name: manufactured by Sakamoto Pharmaceutical Co., Ltd.) and concentrated glycerin (trade name: manufactured by Kao Co., Ltd.) contained in the Japanese Pharmacopoeia can be used as the glycerin. The content of glycerin is preferably from 5 to 25% by mass based on the entire emulsified composition of the present invention.
作為本發明之地蠟,首先可列舉將天然地蠟(ozocerite)精製之源自於礦物的固態烴類。其性質雖類似石蠟,惟具有分子量、比重、黏度、硬度、熔點等高於石蠟之特徵。一般而言,地蠟具有60至80℃左右之熔點,惟在本發明中較佳為熔點為65℃以上的地蠟。又,本發明所稱「地蠟」,除上述之天然生產者外,尚包含一般可替代地蠟使用且屬微晶蠟與流動石蠟之混合物的合成石蠟等。使用合成石蠟時,仍推薦採用其熔點為60至80℃左右,較佳為65℃以上者。本發明中,亦可利用地蠟# 810(商品名:NIKKO RICA股份有限公司)等市售品。相對於本發明乳化組成物全體,本發明之地蠟之含量較佳為0.1~20質量%,更佳為1~15質量%。又,相對於1質量份聚甘油單油酸酯,地蠟之含量較佳為0.1~5質量份。 As the ceresin of the present invention, first, a solid hydrocarbon derived from minerals obtained by refining natural ozocerite may be mentioned. Although its properties are similar to paraffin, it has the characteristics of higher molecular weight, specific gravity, viscosity, hardness and melting point than paraffin. In general, the ceresin has a melting point of about 60 to 80 ° C, but in the present invention, a ceresin having a melting point of 65 ° C or more is preferred. Further, the "ground wax" referred to in the present invention includes, in addition to the above-mentioned natural producers, a synthetic paraffin which is generally used as a wax and which is a mixture of microcrystalline wax and flowing paraffin. When synthetic paraffin is used, it is recommended to use a melting point of about 60 to 80 ° C, preferably 65 ° C or more. In the present invention, a commercially available product such as ozoke #810 (trade name: NIKKO RICA Co., Ltd.) can also be used. The content of the ceres of the present invention is preferably from 0.1 to 20% by mass, more preferably from 1 to 15% by mass, based on the entire emulsified composition of the present invention. Further, the content of the ground wax is preferably 0.1 to 5 parts by mass based on 1 part by mass of the polyglycerol monooleate.
本發明乳化組成物中較佳摻混屬油性成分的 流動石蠟、鯊烷、或白凡士林。 Preferably, the emulsified composition of the present invention is blended with an oily component. Mobile paraffin, squalane, or white petrolatum.
作為流動石蠟,亦可利用HIGHCALL M-352(商品名:KANEDA股份有限公司製)等市售品。相對於本發明乳化組成物全體,流動石蠟之含量較佳為1~30質量%,特佳為5~30質量%。 Commercially available products such as HIGHCALL M-352 (trade name: manufactured by KANEDA Co., Ltd.) can also be used as the liquid paraffin. The content of the liquid paraffin is preferably from 1 to 30% by mass, particularly preferably from 5 to 30% by mass, based on the entire emulsified composition of the present invention.
作為本發明之鯊烷,亦可使用鯊烷-SK(商品名:KURARAY股份有限公司製)等市售品。相對於本發明乳化組成物全體,鯊烷之含量較佳為0.1~20質量%,更佳為0.5~10質量%,再佳為1~10質量%。 Commercial products such as squalane-SK (trade name: manufactured by KURARAY Co., Ltd.) can also be used as the squalane of the present invention. The content of squalane is preferably from 0.1 to 20% by mass, more preferably from 0.5 to 10% by mass, even more preferably from 1 to 10% by mass, based on the entire emulsified composition of the present invention.
作為本發明之白凡士林,亦可利用白凡士林(商品名:PENRECO公司製)等市售品。相對於本發明乳化組成物全體,白凡士林之含量較佳為0.1~20質量%,更佳為0.5~10質量%。 As the white petrolatum of the present invention, a commercially available product such as white petrolatum (trade name: manufactured by PENRECO Co., Ltd.) can be used. The content of white petrolatum is preferably from 0.1 to 20% by mass, more preferably from 0.5 to 10% by mass, based on the entire emulsified composition of the present invention.
再者,本發明乳化組成物較佳為W/O型乳化組成物,作為其劑型可列舉乳油、乳液等。本發明乳化組成物可應用於醫藥品、準醫藥品、化妝品等。 Further, the emulsified composition of the present invention is preferably a W/O type emulsified composition, and examples of the dosage form thereof include an emulsifiable concentrate, an emulsion, and the like. The emulsified composition of the present invention can be applied to pharmaceuticals, quasi-drugs, cosmetics, and the like.
相對於本發明乳化組成物全體,本發明乳化組成物中之水的含量較佳為1~70質量%,更佳為20~70質量%。又,本發明中,在本發明組成物中即使包含50質量%以上的水,亦可調製不會發生分離的W/O型乳化組成物。 The content of water in the emulsified composition of the present invention is preferably from 1 to 70% by mass, more preferably from 20 to 70% by mass, based on the entire emulsified composition of the present invention. Further, in the present invention, even if 50% by mass or more of water is contained in the composition of the present invention, a W/O type emulsified composition which does not cause separation can be prepared.
本發明乳化組成物,在無損本發明效果之範圍內,可以依據其使用目的摻混可根據使用目的摻混於藥物或者化妝品的成分。當摻混藥物時,可根據藥物的種 類,廣泛應用於創傷治癒或消炎止癢、口內炎、痔瘡等。 The emulsified composition of the present invention may be blended with a component which can be blended with a drug or a cosmetic according to the purpose of use, within the range in which the effects of the present invention are not impaired. When blending drugs, depending on the type of drug Class, widely used in wound healing or anti-inflammatory and itching, endophthalmitis, hemorrhoids and so on.
作為可摻混於本發明乳化組成物之藥物,無特殊限制,可列舉例如異丙基甲基酚、鹽酸氯己啶、氯化苯甲基乙氧胺、氯化苄烷銨、地喹氯銨、日本扁柏油等殺菌劑;尿囊素等創傷癒合劑;鹽酸二苯胺明、二苯胺明、馬來酸氯菲安明等抗組織胺劑;乙酸氫化可的松、乙酸氫化潑尼松、氫化可的松、氫化潑尼松、丙酸地塞米松、丙酸貝他米松、戊酸地塞米松、戊酸貝他米松、丙酮氟洛皮質醇、曲安奈德等類固醇劑。作為其他成分,可摻混二丁基羥基甲苯、沒食子酸異丙酯、乙二胺四乙酸鹽等抗氧化劑;薄荷醇、樟腦等冷卻劑;對羥苯甲酸酯、苯甲酸鹽、去氫乙酸、異抗壞血酸、山梨酸等防腐劑;檸檬酸、檸檬酸鹽等pH調節劑;色素、香料等。此外,不限於至此所記載之成分。 The drug which can be blended in the emulsified composition of the present invention is not particularly limited, and examples thereof include isopropylmethylphenol, chlorhexidine hydrochloride, benzyloxyethylamine chloride, benzalkonium chloride, and quinoxaline. Ammonium, Japanese tar tar and other fungicides; wound healing agents such as allantoin; anti-histamines such as diphenylamine, diphenylamine, and chlorpheniramine maleate; hydrocortisone acetate, prednisolone acetate , hydrocortisone, prednisolone, dexamethasone propionate, betamethasone propionate, dexamethasone valerate, betamethasone valerate, acetone fluoxetol, triamcinolone steroids and the like. As other components, an antioxidant such as dibutylhydroxytoluene, isopropyl gallate or ethylenediaminetetraacetate; a coolant such as menthol or camphor; a paraben or a benzoate may be blended; , dehydroacetic acid, isoascorbic acid, sorbic acid and other preservatives; citric acid, citrate and other pH adjusters; pigments, spices and so on. Further, it is not limited to the components described so far.
本發明乳化組成物之製造方法不特別限定。一般而言,可將各成分以適當的製造機混合成均勻的乳液狀或糊狀乳化組成物來製造。 The method for producing the emulsified composition of the present invention is not particularly limited. In general, each component can be produced by mixing into a uniform emulsion or paste-like emulsified composition in an appropriate manufacturing machine.
[實施例] [Examples]
以下茲舉出實施例及比較例對本發明進一步詳細加以說明,惟不限於此等實施例等。此外,實施例及比較例所使用之地蠟為地蠟# 810(商品名:NIKKO RICA股份有限公司;熔點72~76℃)、石蠟為Paraffin Wax 135(商品名:NIPPON SEIRO;熔點55~62℃)。 Hereinafter, the present invention will be further described in detail by way of examples and comparative examples, but is not limited to the examples and the like. Further, the ceres used in the examples and comparative examples were ceresin # 810 (trade name: NIKKO RICA Co., Ltd.; melting point 72 to 76 ° C), and paraffin wax was Paraffin Wax 135 (trade name: NIPPON SEIRO; melting point 55 to 62 °C).
實施例1~6、比較例1~2 Examples 1 to 6 and Comparative Examples 1 to 2
(各乳化組成物之調製法) (modulation method of each emulsified composition)
依下述表1所示配方,秤量各成分,將二甘油單油酸酯、流動石蠟、鯊烷、固體脂肪(地蠟、石蠟或甘油單硬脂酸酯)、白凡士林所成之油相加熱至約80℃予以熔融。添加濃甘油及適量純水調成水相,並加熱至約80℃後,一面使用均質機一面予以添加至油相。攪拌後,經冷卻而得到實施例1~6、及比較例1、2之W/O型乳化組成物。 According to the formula shown in Table 1 below, weigh the ingredients and make the oil phase of diglycerin monooleate, mobile paraffin, squalane, solid fat (ground wax, paraffin or glyceryl monostearate) and white petrolatum. It is heated to about 80 ° C to be melted. The concentrated glycerin and an appropriate amount of pure water were added to prepare an aqueous phase, and after heating to about 80 ° C, the mixture was added to the oil phase while using a homogenizer. After stirring, the W/O type emulsified compositions of Examples 1 to 6 and Comparative Examples 1 and 2 were obtained by cooling.
(試驗例1) (Test Example 1)
將實施例1及比較例1、2之乳化組成物於50℃保存2個月後,基於以下評定基準評定各製劑之性質。 After the emulsified compositions of Example 1 and Comparative Examples 1 and 2 were stored at 50 ° C for 2 months, the properties of the respective formulations were evaluated based on the following criteria.
評定基準 Evaluation basis
○:無分離 ○: no separation
×:有分離 ×: There is separation
將結果示於表1。 The results are shown in Table 1.
由表1可明瞭,摻混有地蠟的實施例1,於50℃保存2個月後仍未看出製劑分離等性質之變化。與此相對,摻混有屬其他固體脂肪之石蠟或甘油單硬脂酸酯的比較例1及2則發生製劑分離。 As is clear from Table 1, Example 1 in which ceresin was blended did not show changes in properties such as separation of the preparation after storage at 50 ° C for 2 months. On the other hand, in Comparative Examples 1 and 2 in which paraffin wax or glyceryl monostearate belonging to other solid fats was blended, the preparation was separated.
(試驗例2) (Test Example 2)
對實施例1~6及比較例1~2之乳化組成物以2700rpm進行離心分離,並評定其穩定性。依以下評定基準評定乳化組成物開始分離前的時間。 The emulsified compositions of Examples 1 to 6 and Comparative Examples 1 and 2 were centrifuged at 2,700 rpm, and the stability thereof was evaluated. The time before the emulsified composition began to separate was evaluated according to the following criteria.
評定基準 Evaluation basis
◎:6小時以內未分離;○:未達0.5~6小時即開始分離;×:未達0.5小時即開始分離。 ◎: not separated within 6 hours; ○: separation was started after 0.5 to 6 hours; ×: separation was started within 0.5 hours.
將結果示於表3。 The results are shown in Table 3.
比較例3 Comparative example 3
依下述表4所示配方,秤量各成分,將二甘油單異硬脂酸酯、流動石蠟、鯊烷、固體脂肪(地蠟、石蠟或甘油單硬脂酸酯)、白凡士林所成之油相加熱至約80℃予以熔融。添加濃甘油及適量純水調成水相,並加熱至約80℃後,一面使用均質機一面予以添加至油相。攪拌後,經冷卻而得到比較例3之W/O型乳化組成物。 According to the formula shown in Table 4 below, weigh each component and make it into diglycerin monoisostearate, mobile paraffin, squalane, solid fat (ground wax, paraffin or glyceryl monostearate) and white petrolatum. The oil phase is heated to about 80 ° C for melting. The concentrated glycerin and an appropriate amount of pure water were added to prepare an aqueous phase, and after heating to about 80 ° C, the mixture was added to the oil phase while using a homogenizer. After stirring, the W/O type emulsified composition of Comparative Example 3 was obtained by cooling.
(試驗例3:使用感試驗) (Test Example 3: feeling test)
就實施例1及比較例3之乳化組成物,評定其展延性。利用展塗計(spreadmeter;離合社(RIGO)製)測定置於25℃ 3分鐘後之展延性。其結果,相對於實施例1之乳化組成物為35.5mm,比較例3為26.5mm。由此可知,本發明乳化組成物比起使用其他界面活性劑者展延性更佳、使用感良好。 The emulsified compositions of Example 1 and Comparative Example 3 were evaluated for their ductility. The stretchability after being placed at 25 ° C for 3 minutes was measured using a spread meter (produced by RIGO). As a result, it was 35.5 mm with respect to the emulsified composition of Example 1, and 26.5 mm of Comparative Example 3. From this, it is understood that the emulsified composition of the present invention has better ductility and a good feeling of use than those using other surfactants.
實施例7、比較例4~5 Example 7, Comparative Example 4~5
(乳化組成物之調製法) (modulation method of emulsified composition)
依下述表5所示配方,秤量各成分,將二甘油單油酸酯、流動石蠟、鯊烷、地蠟、白凡士林所成之油相加熱至約80℃予以熔融。添加濃甘油及適量純水調成水相,並添加氯化苯甲基乙氧胺、馬來酸氯菲安明、尿囊素後,加熱至約80℃使其溶解。一面使用均質機一面予以添加至油相。攪拌後,經冷卻而得到實施例7及比較例4、5之乳化組成物。 According to the formula shown in the following Table 5, each component was weighed, and the oil phase formed by diglycerin monooleate, flowing paraffin, squalane, ozokerite, and white petrolatum was heated to about 80 ° C to be melted. Add concentrated glycerin and an appropriate amount of pure water to prepare an aqueous phase, and add benzyl chloroacetamide, chlorpheniramine maleate and allantoin, and then heat to about 80 ° C to dissolve. Add to the oil phase while using a homogenizer. After stirring, the emulsified compositions of Example 7 and Comparative Examples 4 and 5 were obtained by cooling.
(試驗例4) (Test Example 4)
將實施例7及比較例4、5之乳化組成物在40℃ 75%RH條件下保存6個月後,基於以下評定基準評定各製劑之性質。 After the emulsified compositions of Example 7 and Comparative Examples 4 and 5 were stored at 40 ° C and 75% RH for 6 months, the properties of the respective formulations were evaluated based on the following criteria.
評定基準 Evaluation basis
○:無分離 ○: no separation
×:有分離 ×: There is separation
將結果示於表6。 The results are shown in Table 6.
摻混有地蠟的實施例7在40℃ 75%RH下至6個月未發生分離,經維持穩定之性質。掺混有屬其他固體脂肪之石蠟或甘油單硬脂酸酯的比較例4、5則可看出分離。 Example 7 blended with ceresin did not separate at 40 ° C from 75% RH to 6 months, maintaining stable properties. Comparative Examples 4 and 5 incorporating other solid fat paraffin or glyceryl monostearate showed separation.
(實施例8~10、比較例6) (Examples 8 to 10, Comparative Example 6)
(各乳化組成物之調製法) (modulation method of each emulsified composition)
依下述表7所示配方,秤量各成分,將二甘油單油酸酯、流動石蠟、鯊烷、固體脂肪(地蠟或甘油單硬脂酸酯)、白凡士林所成之油相加熱至約80℃予以熔融。添加濃甘油及適量純水調成水相,並加熱至約80℃後,一面使用均質機一面予以添加至油相。攪拌後,經冷卻而得到實施例8~10、及比較例6之W/O型乳化組成物。 According to the formula shown in Table 7 below, weigh the ingredients and heat the oil phase of diglycerin monooleate, flowing paraffin, squalane, solid fat (homoxyl or glyceryl monostearate) and white petrolatum to It is melted at about 80 °C. The concentrated glycerin and an appropriate amount of pure water were added to prepare an aqueous phase, and after heating to about 80 ° C, the mixture was added to the oil phase while using a homogenizer. After stirring, the W/O type emulsified compositions of Examples 8 to 10 and Comparative Example 6 were obtained by cooling.
對實施例8~10及比較例6之乳化組成物,以2700rpm進行離心分離,以與試驗例2同樣之評定基準評定乳化組成物開始分離前的時間。將結果示於表7。 The emulsified compositions of Examples 8 to 10 and Comparative Example 6 were centrifuged at 2,700 rpm, and the time before the emulsified composition was started to be separated was evaluated on the same basis as in Test Example 2. The results are shown in Table 7.
[產業上可利用性] [Industrial availability]
根據本發明,可提供一種可抑制經時性分離,性質穩定性優良的乳化組成物。本乳化組成物係有用於作為醫藥品.準醫藥品.化妝品等的乳化組成物。 According to the present invention, it is possible to provide an emulsified composition which can suppress temporal separation and is excellent in property stability. This emulsified composition is used as a pharmaceutical. Quasi-pharmaceuticals. An emulsified composition such as cosmetics.
Claims (6)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013088024 | 2013-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201509441A true TW201509441A (en) | 2015-03-16 |
Family
ID=51731443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW103114227A TW201509441A (en) | 2013-04-19 | 2014-04-18 | Emulsification composition |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2014171507A1 (en) |
TW (1) | TW201509441A (en) |
WO (1) | WO2014171507A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6506951B2 (en) * | 2014-11-26 | 2019-04-24 | 株式会社ダリヤ | Skin cosmetics |
JP6893758B2 (en) * | 2015-09-02 | 2021-06-23 | ライオン株式会社 | W / O type emulsified composition |
JP7490580B2 (en) | 2019-02-13 | 2024-05-27 | ミヨシ油脂株式会社 | Compositions containing organic ammonium salts |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5426337A (en) * | 1977-07-28 | 1979-02-27 | Kanebo Ltd | W/o type creamy or milky lotion composition |
JPS62266135A (en) * | 1986-05-12 | 1987-11-18 | Pola Chem Ind Inc | Oil-in-water type emulsified composition |
JP4538377B2 (en) * | 2005-06-03 | 2010-09-08 | マルホ株式会社 | Water-in-oil emulsion composition |
-
2014
- 2014-04-17 WO PCT/JP2014/060919 patent/WO2014171507A1/en active Application Filing
- 2014-04-17 JP JP2015512517A patent/JPWO2014171507A1/en active Pending
- 2014-04-18 TW TW103114227A patent/TW201509441A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2014171507A1 (en) | 2014-10-23 |
JPWO2014171507A1 (en) | 2017-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7384885B2 (en) | Transdermal preparations containing COX inhibitors | |
HUE029786T2 (en) | Ophthalmic emulsion | |
TW201509441A (en) | Emulsification composition | |
JP5965187B2 (en) | Oily ointment | |
KR102317099B1 (en) | Cosmetic composition designed for breaking up algin capsule using chelating effect polymer | |
JP2017078055A (en) | Water-in-oil emulsion composition | |
KR102100311B1 (en) | Vesicle composition, and external preparation for skin and cosmetic preparation each of which contains same | |
JP5912238B2 (en) | Emulsified composition | |
US8617579B2 (en) | Pre-blended mixtures of specific naturally sourced liquid materials structured with naturally sourced high melting point structuring material | |
JP2019099503A (en) | Oral composition | |
US10045965B2 (en) | Transdermal formulation containing COX inhibitors | |
KR102274296B1 (en) | Translucent cosmetic composition | |
US20130272987A1 (en) | Pre-Blended Mixtures of Specific Hydrocarbon Liquids Structured with High Melting Point Structuring Material | |
JP2014070127A (en) | Thickener and external composition | |
JP5662495B2 (en) | Pharmaceutical composition in solubilizer form | |
JP2014111590A (en) | Ointment | |
JP5565995B2 (en) | Antipruritic | |
JP6566574B2 (en) | Ointment base and ointment | |
JP4731472B2 (en) | Sustained release cream | |
JP6634703B2 (en) | External composition | |
JP2022178158A (en) | external composition | |
JP6148794B2 (en) | Gel base and gel preparation | |
JP2022178154A (en) | external composition | |
JP2018168151A (en) | Hair cosmetic | |
TH14569A3 (en) | Pharmacopoeia formulations for external use products |